Molecular Tumor Boards in Clinical Practice-Reference-Cited by-同舟云学术

Molecular Tumor Boards in Clinical Practice

Published:2020-09 Issue:9 Volume:6 Page:738-744
ISSN:2405-8033
Container-title:Trends in Cancer
language:en
Short-container-title:Trends in Cancer

Author:

Luchini Claudio^ORCID,Lawlor Rita T.,Milella Michele,Scarpa Aldo

Funder

Italian Association for Cancer Research

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference15 articles.

1. Precision oncology: origins, optimism, and potential;Prasad;Lancet Oncol.,2016

2. Clinical and technical aspects of genomic diagnostics for precision oncology;Sheikine;J. Clin. Oncol.,2017

3. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT);Mateo;Ann. Oncol.,2018

4. Supporting molecular tumor boards in molecular-guided decision-making – the current status of five German university hospitals;Hinderer;Stud. Health. Technol. Inform.,2017

5. Molecular tumor boards: realizing precision oncology therapy;Patel;Clin. Pharmacol. Ther.,2018

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and opportunities for sarcoma care and research in Latin America: a position paper from the LACOG sarcoma group;The Lancet Regional Health - Americas;2024-02

2. The role of molecular tumor boards in neuro-oncology: a nationwide survey;BMC Cancer;2024-01-19

3. Expert Consensus on Molecular Tumor Boards in Taiwan: Joint Position Paper by the Taiwan Oncology Society and the Taiwan Society of Pathology;Journal of Cancer Research and Practice;2024-01-19

4. Pragmatic Nationwide Master Observational Trial Based on Genomic Alterations in Advanced Solid Tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II Study Protocol KCSG AL-22-09;2024-01-09

5. Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors;JCO Global Oncology;2024-01